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Introduction
The transmembrane activator and calcium modulating cyclophilin 
ligand interactor (TACI), a member of the TNF receptor family (1), 
is found predominantly on lymphocytes. TACI signaling causes 
sustained expression of BLIMP-1 (2), a transcription factor that 
orchestrates maturation of B cells into long-lived antibody-secret-
ing cells (3, 4) and inhibits apoptosis of plasma cells (5); however, 
the full spectrum of functions of TACI is not known. Deficiency 
of TACI in mice and humans causes Ig concentrations in blood to 
be low (hypogammaglobulinemia), impairs long-lived responses 
to encapsulated bacteria and influenza (6–8), and can predispose 
to various combinations of lymphoproliferation, tumor formation, 
and autoimmunity (9, 10). This constellation of findings is called 
common variable immunodeficiency (CVID) and is associated 
with allelic variants of the genes encoding TACI and proteins con-
veying TACI functions (11, 12).
CVID is the most prevalent primary immunodeficiency dis-
ease (13) and differs from other primary immunodeficiency dis-
eases by its late age of onset, usually at ages 20–40 years and 
sometimes much later, and by its range of manifestations includ-
ing various combinations of low levels of serum Ig (hypogamma-
globulinemia), defective cellular immunity, defective control of 
lymphocyte proliferation, autoimmunity, and cancer (14, 15). Yet, 
the most dramatic difference between CVID and other typical 
primary immunodeficiencies concerns the penetrance of disease 
associated with allelic variants of TACI and other receptors. In 
contrast to full penetrance of the null mutations BTK or CD40, 
which cause X-linked agammaglobulinemia, or hyper-IgM syn-
drome, respectively, allelic variants of TACI, such as C104R and 
A181E, which impair TACI function even in the heterozygous state 
(16), usually exhibit no clinically significant defects in immunity 
(17). Thus, Salzer et al. (18) found heterozygous C104R or A181E 
TACI variants in 6.9% of subjects with CVID but also in 2% of 675 
normal adults. The later frequency equals the highest prevalence 
of SNPs found in 1,092 human genomes (19). Other variants that 
impair signaling by TACI are also found, albeit at lower frequen-
cies, in normal individuals (20). Still more curious, individuals 
homozygous for C104R exhibit a milder phenotype of CVID and 
are less likely to develop autoimmunity than are individuals het-
erozygous for C104R (14, 18, 21), and some respond normally to 
vaccination despite having hypogammaglobulinemia (22). The 
vast range of manifestations associated with TACI variants in 
human subjects, from normal to severe CVID, and the reciprocal 
impact of gene dosage on the severity of the disease suggest that 
either background genes exert more impact on phenotype than 
any TACI allele, or the high prevalence of TACI variants is adap-
tive in response to environmental factors, or both.
To consider the latter possibility experimentally, we explored 
the phenotype of TACI deficiency in mice with a fully inbred 
genetic background. Consistent with the human phenotype of 
CVID, mice lacking TACI exhibit hypogammaglobulinemia and 
generate defective long-lived antibody responses to antigen (2, 6, 
7). Still, TACI-deficient mice can generate bursts of IgG (2), owing 
to transient expression of BLIMP-1 caused by DNA double-strand 
breaks accompanying an Ig isotype class switch (2). Accordingly, 
we asked whether the antibodies produced by TACI-deficient mice 
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VH1-72 genes obtained from TACI-deficient mice correlated with 
increased affinity/avidity of the corresponding antibodies, suggest-
ing that the mutated sequences with heightened affinity were effi-
ciently selected in TACI-deficient hosts (Figure 1, D and E).
Our analysis of repeated mutations in distinct B cell clones in 
TACI-deficient and WT mice suggests that TACI deficiency does 
not impair antigen selection (Figure 1E). Consistent with that idea, 
we found accumulation of repeated mutations in the complemen-
tarity-determining regions (CDRs) (Supplemental Figure 1, A–F). 
Of the 312 mutations identified in VH sequences from TACI-defi-
cient mice, 67% were replacement mutations, while in WT mice, 
71% of 164 mutations were replacement mutations, both pre-
sumably driven by antigen selection. Similarly, W to L substitu-
tion at position 33 (Kabat numbering) in VH1-72, a mutation that 
increases the affinity of anti-NP antibodies by a factor of 10 (26), 
was as frequent in sequences from TACI-deficient (67%) mice as 
in those from WT (68%) mice (Supplemental Figure 1).
Light-chain utilization and sequences also suggested that 
TACI deficiency did not impair antigen selection. Supplemental 
Figure 1, B, E, and F show that all the IgG NP–specific mAbs iso-
lated used λ light chains. The light chains sequenced from hybri-
domas derived from TACI-deficient mice used Vλ1 and Vλ2, while 
the light chains sequenced from hybridomas derived from WT 
mice used only Vλ1. The Vλ exons showed recurring mutations in 
the CDR2 regions of both TACI-deficient and WT mice, suggest-
ing that these mutations contribute to antigen selection. In accor-
dance, some of the aa changes are common to both genotypes 
(Supplemental Figure 1, B, E, and F).
The increased frequency of mutations in the VH genes in clones 
originating from TACI-deficient mice suggests that each respond-
ing B cell clone accumulated more mutations per cell cycle and/or 
that each clone underwent more cycles in which somatic hypermu-
tation occurred. The increase was not apparently due to increased or 
protracted expression of Aicda, as TACI-deficient germinal center 
(GC) B cells expressed the same level of Aid mRNA (1.1-fold more, 
P = 0.4) as WT GC B cells. Our results thus suggest that an increase 
in the number of cell cycles during which somatic hypermutation 
occurs (coupled with effective antigen selection) drives the increase 
in high-affinity B cell clones and antibodies in TACI-deficient mice.
B cell–intrinsic TACI limits GC B cell expansion. Somatic hyper-
mutation and selection of B cells expressing receptors with high 
affinity for antigen take place in GCs, where specialized Th cells, 
follicular dendritic cells, and antigen provide conditions needed to 
stimulate and sustain B cell proliferation, somatic hypermutation, 
and selection. We asked whether and how TACI deficiency impacts 
on these processes. TACI-deficient and WT mice were immunized 
with 108 sheep erythrocytes (SRBCs), a standard antigen used to 
elicit T cell–dependent B cell responses, and 7 days later, the spleens 
were harvested for study. Figure 2 shows typical images of the GCs 
of TACI-deficient and WT mice. The GCs of TACI-deficient mice 
were 3.5-fold larger (P < 0.0001), on average, owing to the presence 
of more GC B cells, identified by peanut agglutinin (red), and naive 
B cells, identified by expression of IgD (green) (Figure 2, A and B). 
Seven days after immunization, the GCs of TACI-deficient mice 
contained 3.4-fold more activated B cells, marked by expression of 
CD19, FAS, and GL-7 (identifying a sialic acid glycan on the surface 
of activated B cells) than did the GCs in WT mice (P < 0.0001); 
achieve the avidity and function of antibodies produced by normal 
mice with the same genetic background, whether the antibodies 
protect against environmental pathogens, and, most importantly, 
whether differences in TACI-deficient and normal mice might 
explain the variegated phenotype of TACI variants in man.
Results
TACI deficiency enhances affinity maturation of antigen-specific anti-
bodies. The ability of antibodies to activate complement and tether 
phagocytes and hence to clear pathogens depends in part on their 
avidity for antigen (23). To determine whether TACI deficiency 
impairs affinity of antibodies produced in response to recently 
administered antigen, we immunized mice with a model antigen 
(4-hydroxy-3-nitrophenyacetyl [NP] coupled to an OVA carrier) 
(2, 24), generated hybridomas 40 days later, and measured the 
avidity of NP-specific mAbs from the immunized mice. We pro-
duced 220 NP-specific hybridomas from inbred TACI-deficient 
mice and 77 from inbred WT mice of the same genetic background 
(C57BL/6). The KD of NP-binding IgG was determined by the 
method of Stevens et al. (25). Twenty-two of 23 NP-specific IgG 
mAbs from immunized TACI-deficient mice exhibited high affin-
ity, a KD of less than 4 × 10–10 M, while only 4 of 10 mAbs from 
WT mice exhibited such affinity (Figure 1A). Only 1 NP-specific 
monoclonal IgG clone was encoded by a non VH1-72 gene; its KD 
was 1.8 × 10–10 M. These results were confirmed by BioLayer inter-
ferometry (BLI) (Figure 1B). Thus, contrary to expectations (8), 
TACI-deficient mice can produce antigen-specific, high-affinity 
IgG antibodies in recall responses.
Antibodies of high avidity and affinity in WT mice, and pre-
sumably TACI-deficient mice, originate from B cells that have 
undergone “hypermutation” of Ig variable region exons followed 
by the selection of clones expressing antibodies of higher affinity. 
To weigh the relative contributions of these mechanisms, we com-
pared the sequences of the genes encoding heavy-chain exons of 
NP-specific IgG following PCR amplification from DNA obtained 
from subcloned hybridomas from TACI-deficient and WT mice 
that had been immunized with NP-OVA conjugate. From these 
sequences, we identified and enumerated independent muta-
tions from the VH1-72 germline, the NP-canonical VH1-72 gene 
fragment. Independent mutations were determined by count-
ing mutations in distinct sequences. Sixty-six percent of VH1-72 
sequences from B cells of TACI-deficient mice, but only 32% of 
VH1-72 sequences from B cells of WT mice, had, on average, more 
than 10 mutations per sequence (Figure 1, C and D). We counted 
312 independent mutations in 7,050 nucleotides sequenced 
from VH1-72 of TACI-deficient mice (mutation frequency, 4.4%; 
Supplemental Figure 1D; supplemental material available online 
with this article; doi:10.1172/JCI74428DS1) and only 164 indepen-
dent mutations in 6,090 nucleotides from VH1-72 sequences of WT 
(mutation frequency, 2.7%; Supplemental Figure 1C). Contingency 
analysis revealed that TACI deficiency significantly increased the 
frequency of independent mutations (P < 0.0001; Figure 1, C and 
D). On average, TACI-deficient VH1-72 genes had 8.3 replacement 
mutations per sequence, while WT VH1-72 had only 5.6 replace-
ment mutations per sequence (contingency analysis, P = 0.0005 
by Fisher’s exact test; Figure 1, D and E, and Supplemental Fig-
ure 1, A, C, and D). The frequency of replacement mutations in 
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allotypic (CD45.2+) B cells from quasi-monoclonal (QM) TACI- 
sufficient or QM TACI-deficient mice (6) and/or OVA-primed T cells 
from C57BL/6 (CD45.2+) TACI-deficient or TACI-proficient mice. 
We adoptively transferred CD45.2 TACI-proficient or -deficient 
B and T cells into CD45.1 recipients immunized with NP-OVA at 
the increase persisted at 14 days, when 2.0-fold more activated 
B cells were present (P = 0.0012) (Figure 2, C and D).
We next asked whether TACI deficiency in B cells or T cells or 
both caused expansion of the GC B cell population. To address that 
question, we tested the GC responses in chimeras generated using 
Figure 1. Impact of TACI deficiency on affinity maturation of antibodies produced in response to immunization. (A) KD of mAbs generated from WT and 
TACI-deficient mice. KD (y axis) in nM (the reciprocal of avidity is depicted in blue) of monoclonal anti-NP antibodies (mAbs) encoded by the canonical VH1-72 
(VH186.2) was determined by ascertaining the concentration at equilibrium at which one-half was bound and one-half unbound (25, 45). mAbs from WT 
mice had an average KD of 4.6 × 10
–10, while mAbs from TACI-deficient mice had an average KD of 2.4 × 10
–10 (P = 0.0079, unpaired t test). (B) Comparison of 
mAb KD determined by real-time measurement of association and dissociation rates and BLI, with KD determined at equilibrium by ELISA. (C) Impact of TACI 
on the mutation frequency of VH1-72 encoded by anti-NP antibodies. Frequency of sequences with a given number of mutations is plotted. TACI deficiency 
increased the frequency of independent mutations by more than 2-fold (P < 0.001, contingency analysis). (D) Relationship between frequency of mutations 
and antibody avidity in response to NP. Frequency of mutations in VH1-72 sequences is depicted in relation to avidity at equilibrium of the corresponding 
antibodies. Avidity correlated with the number of mutations (P < 0.0001, Wilcoxon matched-pairs, signed-rank test). (E) Localization of aa substitutions 
in distinct clones encoding VH1-72 heavy chains of anti-NP antibodies obtained from WT and TACI-deficient mice. KD for the corresponding sequences was 
determined by BLI (values are shown on the right). V(D)J, variable(V), diversity (D) and joining (J) gene segments junction region of the Ig heavy chain exon.
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TACI deficiency increases Tfh recruitment to GCs. Because 
T cell help contributes to B cell expansion and selection, we asked 
whether TACI deficiency changes the population of Tfh cells after 
immunization. In fact, WT Tfh cells expressed Taci as much as 
B cells did (Figure 4A). Tfh cells (in TACI-deficient or TACI-profi-
cient mice) also expressed CXCR5, PDL-1, and Bcl6 (Figure 4A). 
Figure 4B shows that the fraction of Tfh cells was increased before 
and 5 and 8 days following immunization. The expansion of Tfh 
cells was due, at least in part, to increased proliferation, since 
TACI-deficient mice had 2-fold and 2.7-fold more BrdU+ Th cells 
than did control mice 7 (P = 0.0066) and 14 (P = 0.0046) days 
after immunization, respectively. The expansion of Th cells was 
secondary to the lack of TACI on B cells adoptively transferred 
into a congenic recipient (Figure 4C). These results suggest that 
B cell–intrinsic TACI deficiency increases the availability of T cell 
help. In a recently published article, Goenka et al. (30) showed 
that while the GC lacks BAFF, a TACI ligand, Tfh-derived BAFF 
contributes to persistence of B cell clones undergoing affinity mat-
uration. Thus, enhanced recruitment of Tfh by TACI-deficient 
B cells may cause enhanced BAFF production at the T-B cell bor-
der, facilitating maintenance of expanded clones and selection of 
mutated B cells. Since B cells recruit Tfh via increased ICOS-L/
ICOS interactions at the T-B follicular border (31), we measured 
the expression of Icos on cultured splenocytes by quantitative 
PCR (qPCR). Splenocytes obtained from TACI-deficient mice 
expressed, on average, 50% more Icos mRNA than did WT GC 
B cells, but this increase was not statistically significant (P = 0.1). 
We did not detect differences in the expression of Il4, Il6, or Il10 in 
TACI-deficient splenocytes or WT cells
TACI deficiency enhances host defense. Gene variants hindering 
expression or function of TACI are associated with CVID manifested 
by a heightened risk of serious infection (14), albeit with profoundly 
varied penetrance in human subjects (18). Accordingly, we asked 
whether TACI deficiency and hypogammaglobulinemia impair 
host defense in mice with a fully inbred background. To address 
that question, we explored the response to Citrobacter rodentium 
(C. rodentium), an intestinal pathogen of mice taken to model human 
enterohemorrhagic and enteropathogenic Escherichia coli (32), 
which cause severe diarrhea and mortality worldwide. After infec-
tion, WT mice exhibit diarrhea, decreased activity, and hunched 
posture; the levels of bacteria peak at 5 to 15 days and clear entirely 
at 21 to 28 days (33). Mice deficient in RAG2 and hence lacking the 
capacity to mount cellular and antibody-mediated responses do not 
clear C. rodentium and often succumb to sepsis within 16 days after 
infection (34). The importance of adaptive immunity and immune 
memory are confirmed by the observation that normal mice previ-
ously exposed to the organism have profoundly fewer organisms in 
the colon 11 days after reinfection (35). Clearance of C. rodentium 
and prevention of sepsis requires a T cell–dependent B cell response, 
as an absence of CD4+ T cells and/or B cells causes infected mice 
to experience persistent infection or death, and administration of 
immune IgG prevents death (34, 36, 37). Despite the importance 
of adaptive immunity in clearing C. rodentium and the association 
of TACI deficiency with CVID, TACI-deficient mice given 109 CFU 
C. rodentium twice, by gavage, cleared the organism faster than did 
WT mice (Figure 5A). Two days after reinfection, 3 of 8 TACI-de-
ficient mice, but only 1 of 9 WT mice, cleared the reinfection 
the time of transfer, and the fraction of CD45.2 GC B cells was 
measured 14 days later. As Figure 2E shows, the deficiency of 
TACI on T cells or B cells (or both) expanded the population of GC 
B cells. The result further suggests that after exposure to antigen, 
TACI might govern such interactions between follicular T cells 
and follicular B cells that delimit the B cell response.
TACI limits GC B cell proliferation. The greater expansion 
of GCs and GC B cell populations in TACI-deficient mice after 
exposure to antigen could reflect increased proliferation, failure 
of B cells to mature (2), and migration and/or decreased apop-
tosis. To distinguish between these possibilities, TACI-deficient 
and WT mice were pulsed with BrdU at various times after 
exposure to antigen, and the incorporation of BrdU into GC B 
cells was measured by flow cytometry. Seven days after immu-
nization with SRBCs, a period when GCs should be expanding 
(27), TACI-deficient mice had 4-fold more GC B cells contain-
ing BrdU than did WT mice (P = 0.002) (Figure 3A). In con-
trast, TACI-deficient and WT mice had the same number of GC 
B cells containing BrdU 14 days and 28 days after immunization, 
a time when GCs usually regress (Figure 3A). These results indi-
cate that the presence of TACI restrains B cell proliferation dur-
ing the period immediately following immunization. However, 
since TACI-deficient mice had 2.3-fold more GC B cells than did 
WT mice 14 days after immunization, factors besides prolifera-
tion, including failure to migrate or to undergo apoptosis, might 
contribute to GC cell expansion.
TACI promotes GC B cell apoptosis and increases cIAP expres-
sion. Since apoptosis of B cells failing to express a functional Ig or 
competing poorly for antigen or T cell help normally controls GC 
expansion, we asked whether TACI deficiency impairs apoptosis 
of GC B cells. Consistent with that possibility, Figure 3, B and C, 
shows that 7 days after immunization with SRBCs, TACI-defi-
cient mice had 2.2-fold fewer TUNEL+ cells than did WT mice 
(P = 0.0055). To confirm that TACI impairs apoptosis, we asked 
whether inhibition of TACI suppresses caspase 3 activation in 
stimulated B cells. B cells from WT and TACI-deficient mice were 
incubated with anti-CD40 antibody and IL-4 (2) for 48 hours in 
the presence or absence of soluble TACI-Fc, which competes for 
TACI ligands. As Figure 3D shows, the frequency of apoptotic 
B cells was reduced in cultures containing TACI-Fc (paired t 
test, P = 0.04), as was seen in cultures from TACI-deficient mice 
(P = 0.01). While various pathways might induce apoptosis in 
stimulated cells, Kanno et al. (28) recently reported that TACI 
induces apoptosis by increasing the association between TRAF2 
and cIAP (cellular inhibitor of apoptosis). Consistent with this 
report, the GC B cells of TACI-deficient mice immunized with 
SRBCs contained less cIAP than did GC B cells from the WT mice 
(P = 0.03 by Mann-Whitney U test) (Figure 3E). The reduction 
in cIap mRNA was specific to B cells, since TACI-proficient and 
TACI-deficient T helper follicular (Tfh) cells had similar expres-
sion levels of cIap (Figure 3F). Thus, expansion of GC B cells in 
TACI deficiency reflects, at least in part, impaired apoptosis of 
stimulated B cells and decreasing cIap expression. If, as Khalil 
et al. (29) suggested, selection occurs once every cell cycle, then 
increasing proliferation of GC B cells coupled with decreased 
apoptosis will improve the chances of selection for mutations of 
the V region that augment affinity/avidity for antigen.
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shows that IgG in sera obtained from 
TACI-deficient mice 5 days after reinfec-
tion with C. rodentium required, on aver-
age, 48% less intimin than did WT sera to 
reduce by 50% the concentration of free 
anti-intimin in solution (P = 0.01) (Figure 
5B), indicating that TACI-deficient mice 
produce IgG antibodies with increased 
avidity for intimin. If the avidity of sera 
IgG determines C. rodentium clearance, 
we expect to observe a correlative rela-
tionship between the KD and the number 
of microbes in the feces. Figure 5C shows 
that the concentration of intimin needed 
to reduce the anti-intimin IgG in solution 
by half correlated in a linear manner with 
the number of microbes in the feces 5 days 
after reinfection.
To determine whether antibod-
ies produced by TACI-deficient mice 
infected with C. rodentium better 
enhanced clearance of the organism 
than antibodies produced by WT mice, 
we transferred sera from twice-infected 
animals into RAG1-deficient mice, which 
were then infected. Figure 6 shows that 
RAG1-deficient mice given sera from 
previously infected TACI-deficient mice 
had 9-fold fewer organisms in the feces 
than did RAG1-deficient mice given sera 
from previously infected WT mice and 
22-fold fewer organisms than did mice 
given saline. Thus, despite all the lim-
itations TACI deficiency may impose on 
immune responses, it enhances the abil-
ity of mice to control and clear C. roden-
tium, in part, owing to enhanced affinity 
of the antibodies produced.
Discussion
Primary immunodeficiency diseases such as the DiGeorge syn-
drome, severe combined immunodeficiency syndrome, sex-linked 
agammaglobulinemia, and hyper-IgM syndrome are rare, typical 
genotype frequencies approaching 1 × 106 and almost invariably 
manifest as severe infection early in life, and, without aggressive 
medical care, result in early demise (32). In contrast, CVID appears 
first in adults, exhibits a variegate phenotype (39), and the most fre-
quent genotypes associated with the disease have an aggregate geno-
type frequency of at least 2% (18). In fact, contrasting with genotypes 
known to cause most primary immunodeficiencies, those targeting 
the TACI gene that are most frequently associated with CVID can be 
found in a large fraction — approximately 2% — of normal individ-
uals (18). Here, we show that the phenotype of TACI deficiency in 
inbred mice, while resembling CVID in some respects such as base-
line hypogammaglobulinemia, includes the ability to produce a burst 
of IgG of high affinity in response to antigen and infection, allowing 
affected mice to clear an enteric pathogen that models those that are 
(Figure 5A). Five days after reinfection, all but 1 TACI-deficient 
mouse, but only 60% of WT mice, had cleared the organisms 
(Figure 5A). Consistent with an enhanced memory response, TACI- 
deficient mice had an increased frequency of C. rodentium–binding 
B cells (on average, 35%) compared with that seen in WT mice (on aver-
age, 27%) 10 days after reinfection (Supplemental Figure 4). These 
results indicate that TACI-deficient mice mount an enhanced mem-
ory response that accelerates clearance of C. rodentium.
Given the faster clearance of C. rodentium by TACI-deficient 
mice, we asked whether the response could reflect increased 
avidity of antibodies elicited by the infecting organism. While 
the neutralizing targets of anti-Citrobacter antibodies are incom-
pletely known, Ferreira et al. (38) and Ghaem-Maghami et al. (35) 
showed that antibodies directed against intimin, a surface protein, 
protect. Accordingly, we tested the average avidity of IgG antibod-
ies directed against intimin in TACI-deficient and WT mice. To 
estimate the average avidity of specific antibodies in a polyclonal 
serum, we measured the amount of purified intimin needed to 
reduce by 50% the binding of anti-intimin antibodies. Figure 5B 
Figure 2. Impact of TACI deficiency on GC B cells. (A) Identification of GCs with peanut agglutinin (red) 
and naive B cells with anti-IgD (green) in frozen tissue sections prepared from spleens 7 days after 
immunization with SRBCs, counterstained with DAPI (blue). TACI deficiency increased GC and naive  
B cells. Original  magnification, ×200. (B) Area of GCs was measured with ImageJ software. Each point 
corresponds to the area of 1 GC. On average, GCs in TACI-deficient mice were larger than GCs in C57BL/6 
mice (P < 0.0001). (C and D) GCs were identified with anti-CD19, anti–GL7 (50), and anti-FAS (CD95) 
mAbs and analyzed by FACS. Shown are CD19+ GC cells. GC B cells were increased in TACI-deficient mice 
(day 7, P < 0.0001; day 14, P = 0.0012). (E) Impact of T cell or B cell TACI deficiency on the number of GC 
B cells. C57BL/6 mice or Taci-KO (CD45.2) mice immunized with OVA were used as a source of  
T cells (T-WT and T-KO, respectively) for transfer into WT CD45.1+ mice. CD45.2 B cells isolated from QM 
or from QM-Taci-KO mice (B-WT and B-KO, respectively) were transferred along with the T cells in the 
combinations indicated. The number of CD45.2 GC B cells in recipients of CD45.2 TACI-deficient or pro-
ficient B or T cells is shown as a proportion of all GC B cells. Multiple comparison tests (1-way ANOVA 
and Holm-Sidak’s) revealed P = 0.003 for T-KO/B-WT versus T-WT/B-WT; P = 0.001 for  
T-KO/B-KO versus T-WT/B-WT; and P = 0.0025 for T-WT/B-KO versus T-WT/B-WT.
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the most common cause of severe gastroenteritis. The protective 
impact of TACI deficiency might thus explain the high frequency of 
mutant alleles of TACI in the normal population.
Our results suggest that deficiency in TACI, whether complete, 
as in the mice we studied, or partial, as in most human subjects 
with common variant alleles, does not invariably impose a biologi-
cal cost, but might be adaptive in communities with a high burden 
of certain pathogens. Consistent with this concept is the high fre-
quency (2%) of alleles associated with CVID in normal individuals 
(18) and the fact that the vast majority of humans with CVID have 
1 normal TACI allele (18). Martinez-Gallo et al. (40) found that sib-
lings of subjects with CVID carrying the same TACI variants had 
assayable defects in B cell function but no manifestations of dis-
ease (no hypogamaglobulinemia, lymphoproliferation, or infec-
tious complications). Importantly, B cells from these healthy sib-
lings with TACI mutations had appreciably less TACI expression, 
bound less APRIL, did not increase TACI expression in response 
to TLR9 activation, and had suboptimal AICDA induction in 
response to TACI stimulation than did B cells from siblings with 
fully WT alleles. If mutations in TACI and related genes are nec-
essary, they are clearly not sufficient for CVID to be manifest, and 
a fuller understanding of the pathogenesis of CVID might depend 
on identifying other predisposing genes or environmental factors.
The laboratory and clinical phenotypes of TACI deficiency, 
both in mice and humans, appear contradictory in some respects. 
The simultaneous presence of hypogammaglobulinemia and 
increased resistance to enteric infection has been discussed above. 
A differential propensity for autoimmunity in those with homozy-
gous or heterozygous TACI-mutant alleles would appear to pres-
ent yet another contradiction. Yong et al. (14) and Salzer et al. (18) 
found that rare individuals with homozygous TACI mutations have 
profound B cell deficiencies; yet, these individuals are less likely to 
develop autoimmune disease than are individuals with heterozy-
gous mutations (21). Our finding that TACI enhances apoptosis of 
Figure 3. Impact of TACI deficiency on B cell proliferation and apoptosis. (A) Number of proliferating GC B cells in WT and TACI-deficient mice at 7, 14, 
or 28 days after immunization with SRBCs. Percentages of BrdU+ GC cells (CD19+GL7+FAS+). TACI deficiency increased proliferation of GC cells 7 days after 
immunization (P = 0.0002, Holm-Sidak test). (B) Immunofluorescence analysis of GC cell apoptosis. Apoptotic cells were identified by TUNEL, labeled 
ends were detected with anti-BrdU antibodies (green, upper diagrams and red, lower diagrams), and cells were counterstained with DAPI. Lower diagrams 
show costaining with anti-GL7 mAbs (green). Results are representative of 6 distinct sections obtained from 2 WT mice and 3 TACI-deficient mice. Original 
magnification, ×200. (C) Enumeration of apoptotic TUNEL+ GC cells. Taci-KO mice had fewer TUNEL+ cells per GC (P = 0.0012, Mann-Whitney U test). (D) 
Impact of TACI ligand blockade on B cell apoptosis. WT or Taci-KO splenic B cells were cultured with anti-CD40 and IL-4 in the presence or absence of TACI-
Fc to inhibit TACI signaling. After 48 hours, caspase 3+ cells were enumerated by FACS. TACI deficiency or impaired TACI function decreased apoptosis 
after B cell activation, (P < 0.05, Mann-Whitney U test). (E and F) Relative expression by qPCR of cellular inhibitor of apoptosis (cIap) by GC B cells (E) or 
Tfh cells (F) 14 days after immunization with SRBCs. Expression of cIap was quantified in cDNA by qPCR reactions using specific primers and SYBR Green 
incorporation (P < 0.05, Mann-Whitney U test).
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activated B cells in the GC and prior reports that TACI promotes 
differentiation and survival of plasma cells (2, 5) might together 
suggest an explanation. A complete absence of TACI function 
impairs control of GC reactions, perhaps allowing the production 
of autoantibodies in response to immunization; however, it may 
also preclude the enduring production of autoantibodies and thus 
autoimmune disease. Partial TACI deficiency impairs the control 
of lymphoproliferation as much as its complete absence does, but 
allows the ongoing production of autoantibodies, as it does not 
block Ig secretion to the same degree.
Thus, certain TACI-mutant alleles and the deficiency in expres-
sion and function of TACI they cause might be adaptive in popu-
lations, especially the young, who are vulnerable to enteric or non-
enteric pathogens controlled by rapidly produced high-affinity IgG. 
The cellular mechanism of this protective response, apparently 
including marked expansion of antigen-responsive GC B cells that 
allow accelerated affinity maturation, might, however, engender 
the lymphoproliferative disease, autoimmunity, and cancer that 
plague those with CVID later in life.
Methods
Mice
WT C57BL/6 mice (CD45.2+), 
CD45.1, or RAG1-deficient congenic 
mice were purchased from The 
Jackson Laboratory. Taci-KO mice 
have been previously described (2, 
6). Taci-KO mice were backcrossed 
onto a C57BL/6 background for 
12 generations. The fraction of loci 
still heterozygous at the twelfth 
generation of backcrossing is 
1/211 = 4.9 × 10–4. Hence, the genome 
is over 99.95% identical to C57BL/6, 
except the regions flanking the 
deletion of exons 1 and 2 of the Taci 
gene in mouse chromosome 11 (7). 
Since contribution of the 129 strains 
encode a Casp11 variant that causes 
impaired IL-1β responses to E. coli, 
C. rodentium, and V. cholerae (41), 
we confirmed that the mice were 
fully inbred to this background by 
skin transplantation. In agreement 
with their C57BL/6 background, 
TACI-deficient B cells expressed 
IgMb (Supplemental Figure 2), and 
the VH genes isolated from B cells 
responding to C. rodentium matched 
C57BL/6 germline alleles (Supple-
mental Figure 3). Mice were housed 
in a specific pathogen-free facility at 
the University of Michigan.
Flow cytometry and antibodies
Fluorochrome-conjugated anti-
mouse CD19 (1D3), CD4 (L3T4), 
CD95 (FAS, JO2), CXCR5 (2G8), 
B220 (RA3-6B2), IgMb (IF6-78), and T and B cell activation antigen 
(GL7) antibodies were purchased from BD Biosciences. C. rodentium 
expressing GFP was a gift of B. Vallance (University of British Colum-
bia, Vancouver, Canada). Phycoerythrin-conjugated (PE-conjugated) 
anti-PD1 (RMP1-30) antibody was purchased from eBioscience. Data 
were acquired with a BD FACS Canto II and analyzed using FACSDiva, 
version 6.1.1 software (both from BD Biosciences).
Apoptosis assay
B cells isolated from spleens using a B cell isolation kit (Miltenyi 
Biotec) and cultured for 2 days with 5 μg/ml hamster anti-mouse 
CD40 antibody (HM40-3, BD Biosciences), with or without 2 μg/ml 
TACI-Fc (Enzo Life Sciences), were stained with anti–active caspase 
3 antibody (Abcam). Active caspase 3–positive cells were detected 
by flow cytometry.
Adoptive transfer
Cell transfer. QM B cells and T cells were isolated (B cell isolation or 
pan T cell isolation kit; Miltenyi Biotec) from spleens of nonimmunized 
Figure 4. Comparison of the phenotype and fraction of Tfh cells in spleens of immunized WT or TACI-de-
ficient mice. (A) TACI expression by GC cells and Tfh cells. Tfh cells were identified as CD4+CXCR5+ and PD1+ 
by FACS (upper panel) and tested for expression of Bcl6 or Taci mRNA by qPCR (middle and lower panels, 
respectively). Tfh cells from TACI-deficient mice expressed as much Bcl6 as those from WT mice (middle panel). 
Taci expression by T cells was equivalent to that in GC B cells (lower panel). (B) Relative number of Tfh cells in 
spleens of WT and TACI-deficient mice before (Pre-I) and 5, 8, and 28 days after immunization with SRBCs. 
Frequencies of Tfh cells in C57BL/6 and Taci-KO mice were compared by 1-way ANOVA and Holm-Sidak multiple 
comparison tests. Pre-I, P = 0.0015; day 5, P = 0.0004; day 8, P < 0.0001; day 28, P > 0.9999 was nonsignificant. 
(C) Impact of TACI expression by B and T cells on the size of the Th cell population. Number of Th cells of donor 
(CD45.2+) or recipient origin (CD45.1+) was determined in chimeras reconstituted as shown in Figure 3 relative to 
chimeras reconstituted with WT-T and WT-QM B cells, 8 days after immunization with 100 μg NP conjugated 
with OVA. Increase in the number of CD4+ Th cells was secondary to B cell–intrinsic TACI deficiency. Comparisons 
by 1-way ANOVA and Holm-Sidak multiple comparison tests. ***P = 0.0001; **P = 0.0013.
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anti-IgD antibody (BioLegend) and mounted with ProLong Gold Antif-
ade Reagent with DAPI (Invitrogen). Digital images were obtained 
with a Leica DM6000B microscope and with Leica Application Suite 
Advanced Fluorescence, version 1.9.0 (both from Leica Microsystems).
Real-time reverse transcriptase-PCR
RNA from sorted GC B cells or Tfh cells was extracted using an RNeasy 
Plus Mini Kit (QIAGEN). cDNA was obtained with a SuperScript III 
First-Strand Synthesis System (Invitrogen). qPCR reactions were run 
on a Mastercycler ep realplex system (Eppendorf), and quantified 
by FastStart Universal SYBR Green Master (Roche Applied Science) 
incorporation using the primers listed in the Supplemental Methods.
Quantification of Icos, Cd40l, Il4, Il6, and Il10 was performed by 
qPCR in cDNA obtained directly from the lysate of 106 splenocytes 
(lysis buffer consisted of 1% 1 M Tris, pH 8.0 and 2.5% rRNasin in 
DNase/RNase-free water) after 3 days in culture with 2.5 μg/ml IL-4 
(R&D Systems) and 1 μg/ml anti-mCD40 (HM40-3; BioLegend) in 
RPMI 1640 supplemented with 10% FBS, penicillin, streptomycin, 
glutamine, and 20 μM 2-mercapto-ethanol. Cells were obtained from 
mice or from spleens of mice primed with 100 μg OVA (Sigma-Aldrich) 
7 days earlier, respectively. Five million B cells and 5 million T cells 
were injected into the tail vein of congenic C57BL/6 (CD45.1) mice 
(The Jackson Laboratory). Mice were immunized with 100 μg NP con-
jugated with OVA (NP-OVA; Biosearch Technologies) in an emulsion 
prepared with incomplete Freund’s adjuvant (Difco Laboratories).
Sera transfer. Sera were obtained from 12 Taci-KO or 12 WT mice, 
infected twice with 1 × 109 C. rodentium, 30 days apart, 10 days after 
the second inoculation. WT mice sera had, on average, 819.6 μg/ml 
IgG, and Taci-KO mice sera had, on average, 554.6 μg/ml IgG. Serum 
from each mouse (200 μl) was transferred into RAG1-deficient mice 
by i.v. injection into the tail. Ten RAG1-deficient mice received sera 
from Taci-KO mice or from WT mice. An additional 10 RAG1-deficient 
mice received 200 μl saline instead. Feces were obtained 3 days after 
infection and sera transfer and bacteria CFU counted.
Proliferation assay
C57BL/6 or TACI-deficient mice immunized with 2 × 108 SRBCs 
(Innovative Research) were injected i.p. with 2 mg BrdU 24 hours 
prior to analysis. BrdU incorporated into cells was detected with 
FITC-conjugated anti-BrdU antibody according to the manufactur-
er’s instructions (BD Biosciences).
TUNEL assay
TUNEL assay was performed on 7-micron-thick frozen sections using 
an In Situ Cell Death Detection Kit (Roche Applied Science) according 
to the manufacturer’s instructions. Sections were stained with FITC- 
labeled PNA (Vector Laboratories) or with Alexa Fluor 488–conjugated 
Figure 5. Impact of TACI deficiency on resistance to C. 
rodentium. C. rodentium (1 × 109) were administered by 
oral gavage to WT or TACI-deficient mice twice, 45 days 
apart. (A) Number of C. rodentium in stool 2 and 5 days 
after the second inoculation. Number of C. rodentium 
per 1 g of feces was determined by counting colonies 
in MacConkey agar seeded with serial dilutions of fecal 
suspensions. Contingency analysis indicated that TACI- 
deficient mice cleared C. rodentium faster than did WT 
mice (P = 0.0084). (B) Impact of TACI deficiency on avidity 
of anti-intimin antibodies in mice infected repeatedly with 
C. rodentium. Five days after reinfection with C. roden-
tium, the avidity of anti-intimin antibodies in serum was 
determined by the concentration of intimin needed to 
reduce the concentration of unbound anti-intimin IgG by 
one-half (tested by ELISA). Comparisons between groups 
were by Mann-Whitney U test (P = 0.0051). (C) Relation-
ship between the average avidity of anti-intimin antibod-
ies and the number of C. rodentium in feces. Number of  
C. rodentium correlated linearly with the relative avidity of 
anti-intimin antibodies in serum.
Figure 6. Number of C. rodentium bacteria in feces of RAG1-deficient 
mice after adoptive transfer of sera from infected TACI-deficient or WT 
mice. Number of bacteria in feces of RAG1-deficient mice 3 days after 
infection with 1 × 109 CFU C. rodentium and transfer of 200 μl sera (i.v.) from 
C57BL/6 mice or TACI-deficient mice, obtained 10 days after reinfection. 
Control RAG1-deficient mice were administered saline instead of sera and 
infected with 1 × 109 CFU C. rodentium. Comparisons between groups were 
by Mann-Whitney U test. P = 0.0157 for Taci-KO versus C57BL/6; P = 0.0176 
for TACI versus saline.
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ELISA
Anti-NP antibodies were measured by ELISA as previously described 
(42). Anti-intimin antibodies were measured by ELISA on MaxiSorp 
plates (Nunc) coated with 50 μl of 0.5 μg/ml intimin in PBS. Absor-
bance was read at 405 nm with a Synergy 2 microplate reader (Biotec 
Laboratories) and results analyzed using Gen5 Data Analysis Soft-
ware, version 1.04.5 (BioTek).
Bioluminescence imaging
Bioluminescence imaging (BLI) was run at 25°C with Octet RED 
(ForteBio) (46–48). KD was deduced from association and dissocia-
tion rates of NP-specific Ig (in dilutions of 0.3–10 nM) and measured 
with super streptavidin sensors (ForteBio) loaded with biotinylated 
NP4-BSA (Biosearch Technologies). Data were processed with a 
double-reference subtraction and analyzed with ForteBio Data 
Analysis Software, version 7.0.
Citrobacter infection
C57BL/6 or TACI-deficient mice were inoculated with 1 × 109 of 
C. rodentium twice, and the microbe load was determined as pre-
viously described (49). Infection was considered cleared when no 
colonies were detected in the nondiluted feces suspensions.
Statistics
Data are presented as the mean ± SEM in all figures in which error 
bars are shown. Statistical analysis was performed using GraphPad 
Prism software, version 6 (GraphPad Software). Distributions of 2 
unmatched groups compared using Mann Whitney test. Comparisons 
of more than 2 groups were by ANOVA. Categorical variables were 
compared using χ2 or Fisher’s exact test analysis. A P value of less than 
0.05 was considered statistically significant.
Study approval
All animal procedures were approved by the University of Michigan 
Committee on the Use and Care of Animals.
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Taci-KO or WT mice using TaqMan FAM-MGB probes and primers 
(Invitrogen). Quantification of Aicda expression was performed by 
qPCR in cDNA using TaqMan FAM-MGB probes and primers. cDNA 
was obtained directly from the lysate of 103 cells (lysis buffer was com-
posed of 1% 1 M Tris, pH 8.0 and 2.5% rRNasin in DNase/RNase-free 
water) obtained from sorted GC B cells from mice (TACI-deficient or 
WT) injected 10 days earlier with SRBCs. qPCR was performed in trip-
licate in 3 mice of each strain.
Monoclonal antibodies
Hybridomas were obtained from splenocytes fused with NS-1 partners 
at the University of Michigan Hybridoma Core. Hybridoma clones 
producing anti-NP antibodies were identified by ELISA. Isotyping of 
NP-specific antibodies was also done by ELISA as previously described 
(42). Hybridomas were generated from 3 TACI-deficient mice and 2 
WT C57BL/6 mice. Monoclonality was confirmed by PCR.
Sequencing
DNA obtained from hybridoma clones was amplified using a VH1-
72–specific (IMGT; refs. 43, 44) forward primer or universal forward 
primers for clones containing other VH genes and with a JH4 reverse 
primer. The nested PCR used the same forward primer and reverse 
primers located on the J1-J2 intron (see Supplemental Methods). PCR 
products were isolated from agarose gels using the QIAquick Gel 
Extraction kit (QIAGEN) and directly sequenced from both ends at 
the University of Michigan DNA Sequencing Core. Each raw chroma-
togram was analyzed using FinchTV, version 1.4.0 (Geospiza Inc.).
Affinity measurements
The affinity/avidity to NP of anti–NP IgG was determined by ELISA from 
the concentration of free anti–NP IgG at equilibrium, with serial dilutions 
of NP-BSA (100 nM to 0.1 nM). Hybridoma supernatants containing 2 
nM IgG were incubated at room temperature overnight with NP-BSA.
The KD was calculated according to the formula below (25, 45):
   (Equation 1)
A0 is OD405 without competitor (NP-BSA); Ai is OD405 with competi-
tor at the concentration of Li; and Li is the concentration of competitor.
The relative affinity/avidity of anti-intimin IgG was deduced from 
the intimin concentration required to reduce the concentration of non-
bound anti-intimin IgG by half.
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